Ultra-small lipid carriers with adjustable release profiles for synergistic treatment of drug-resistant ovarian cancer

Multidrug resistance has dramatically compromised the effectiveness of paclitaxel (PTX). The combined application of PTX and tetrandrine (TET) is a promising avenue in drug-resistant cancer therapy. However, poor drug release and limited intracellular drug accumulation greatly impede this combinatio...

Full description

Saved in:
Bibliographic Details
Published in:Nanotechnology 2022-08, Vol.33 (35), p.355102
Main Authors: Wang, Chenghao, Wang, Jia, Han, Xinyu, Liu, Jiaxin, Ma, Mengchao, Tian, Siyu, Zhang, Liying, Tang, Jingling
Format: Article
Language:English
Subjects:
Cell Line, Tumor
combination therapy
controlled release
Drug Carriers
Female
Humans
Lipids
multidrug resistance
Nanoparticles
nanostructured lipid carriers
Ovarian Neoplasms - drug therapy
paclitaxel
Paclitaxel - pharmacology
Pharmaceutical Preparations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug resistance has dramatically compromised the effectiveness of paclitaxel (PTX). The combined application of PTX and tetrandrine (TET) is a promising avenue in drug-resistant cancer therapy. However, poor drug release and limited intracellular drug accumulation greatly impede this combinational antitumor therapy. To address this problem, we successfully developed a tunable controlled release lipid platform (PT@usNLC) for coordinated drug delivery. The drug release rate of PT@usNLC can be tuned by varying the lipid ratio, which has potential to maximize the therapeutic effects of combined drugs. The TET release rate from PT@usNLC was faster than PTX, which could restore the sensitivity of tumor cells to PTX and exert a synergistic antitumor effect. The appropriate size of PT@usNLC could effectively increase the intracellular drug accumulation. Both and studies revealed that PT@usNLC significantly enhanced the therapeutic effect compared to conventional therapies. This study provides a new strategy for resistant ovarian cancer therapy.
ISSN:0957-4484
1361-6528
DOI:10.1088/1361-6528/ac18d6